ADC Therapeutics SA announced that, on December 15, 2022, Robert A. Schmidt informed the Company of his resignation as the Company's Chief Accounting Officer, effective December 30, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.3 USD | +4.43% | -3.51% | +98.80% |
30/05 | Cantor Fitzgerald Initiates ADC Therapeutics at Overweight Rating | MT |
07/05 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+98.80% | 32Cr | |
+18.15% | 12TCr | |
+18.02% | 11TCr | |
+5.07% | 2.29TCr | |
-12.75% | 2.22TCr | |
-9.86% | 1.7TCr | |
-14.97% | 1.69TCr | |
-39.94% | 1.69TCr | |
+2.80% | 1.36TCr | |
+27.39% | 1.16TCr |
- Stock Market
- Equities
- ADCT Stock
- News ADC Therapeutics SA
- ADC Therapeutics SA Announces Resignation of Robert A. Schmidt as Company’S Chief Accounting Officer, Effective December 30, 2022